Skip to main content
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC — Investor Relations & Filings

Ticker · ADAP ISIN · US00653A1079 LEI · 549300UUNWK8TRT5EW12 US Manufacturing
Open in API
Filings indexed 807 across all filing types
Latest filing 2015-04-27 Capital/Financing Update
Country GB United Kingdom
Listing US ADAP

About Adaptimmune Therapeutics PLC

https://www.adaptimmune.com/

Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.

Recent filings

Filing Released Lang Actions
F-1/A
Capital/Financing Update Classification · 95% confidence The document is titled as an Amendment No. 1 to Form F-1 Registration Statement filed with the SEC, which is a registration statement under the Securities Act of 1933. It includes details about the company's initial public offering (IPO), such as the number of shares to be registered, offering price range, underwriting details, and corporate reorganization information. The document is a preliminary prospectus related to the IPO and registration of securities, not a financial report, earnings release, or management discussion. It is a regulatory filing related to capital raising and securities registration. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2015-04-27 English
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is a letter from the company's legal counsel to the SEC staff regarding a Registration Statement on Form F-1 filed by Adaptimmune Therapeutics plc. It discusses clarifications about the company's operating cycle and accounting treatment related to a collaboration agreement with GlaxoSmithKline. The letter references regulatory comments and provides detailed explanations about accounting standards (IAS 1) and the company's revenue recognition policies. The document is a correspondence related to a regulatory filing (Form F-1) and does not contain financial statements, earnings data, or management discussion. It is primarily a regulatory communication and legal explanation rather than a financial report or announcement. Therefore, it fits best under Regulatory Filings (RNS).
2015-04-22 English
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is a letter from the company's legal counsel to the SEC staff regarding the Registration Statement on Form F-1 for an initial public offering (IPO). It discusses valuation analyses of the company's shares prior to the IPO, references the Registration Statement, and addresses SEC comment letters. The document is a correspondence related to the registration and offering process, not the registration statement itself or a financial report. It does not contain financial statements or substantive financial data but rather explanations and legal commentary on the valuation and IPO pricing. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory correspondence and filings that do not fit other specific categories.
2015-04-18 English
Regulatory Filings 2015
Regulatory Filings
2015-04-17 English
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is a detailed comment letter response from a company to the SEC staff regarding a Draft Registration Statement on Form F-1. It discusses revisions to the registration statement, responses to SEC comments, and includes detailed disclosures about the company's product pipeline, financial information, risk factors, and valuation. The presence of references to Form F-1, registration statements, and detailed responses to SEC comments indicates this is part of a registration process for an initial public offering or similar capital market transaction. This type of document is regulatory in nature and is not a financial report like an annual or quarterly report, nor is it a simple announcement or presentation. It is a regulatory filing responding to SEC comments on a registration statement. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2015-04-06 English
F-1
Capital/Financing Update Classification · 100% confidence The document is a Form F-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) under the Securities Act of 1933. It is a registration statement for an initial public offering (IPO) of American Depositary Shares (ADSs) by Adaptimmune Therapeutics plc. The text includes details about the offering, underwriting, risk factors, financial information, corporate reorganization, and other disclosures typical of an IPO prospectus. This type of filing is a regulatory registration statement for securities offering, not an annual report, earnings release, or other financial report. It is not a report publication announcement or a certification. The document is a primary registration statement for a securities offering, which fits the category of Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes through an IPO.
2015-04-06 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.